Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neostigmine and Glycopyrrolate for Bowel Care in SCI
NCT02370433Phase 1Unknown
- Sponsor
- James J. Peters Veterans Affairs Medical Center
- Start
- Dec 2012
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of neostigmine in neurogenic bowel (NBD) (3 arms), sponsored by James J. Peters Veterans Affairs Medical Center. Primary endpoints: Biological Response to Study Medication (Time to complete BC) at 24 months and Biological Response to Study Medication (Reductions/increases in secondary methods) at 24 months. Status: unknown.
02
Drugs
neostigmine
03
Conditions
neurogenic bowel (NBD)
Beyond the preview
Go deeper on NCT02370433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02370433.